{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Following the appearance of either immediate or delayed infusion-associated events, subsequent', 'doses may be pre-treated with diphenhydramine (1 to 1.25 mg/kg IV; maximum of 50 mg),', 'ranitidine (50 mg IV), famotidine (0.5 mg/kg IV), dexamethasone (0.4 mg/kg IV; maximum of', '20 mg), and/or acetaminophen (500 mg). All subsequent infusions will be administered over', 'approximately 90 minutes (but not less than 80 minutes) with vital signs monitored every', '15 minutes from the start of the infusion through 60 minutes after infusion completion.', 'In general, the decision to continue dosing should take into consideration the potential benefit', 'and risk to a subject.', 'Any severe drug-related AE must revert to mild or moderate in intensity at least 2 weeks prior to', 'the next scheduled dose in order for the dose to be administered; if the AE remains severe in', 'intensity within 2 weeks of the next scheduled dose, the subject will be withdrawn from', 'treatment.', 'Increase in blood glucose is a known AE observed in previous clinical trials with teprotumumab', 'and other IGF-1R antagonists and is known to respond to treatment. Since a referral for treatment', 'of hyperglycemia may take some time, if the Investigator considers it appropriate to continue the', 'subject in the study, the next scheduled infusion visit may be skipped to allow modified anti-', 'diabetic treatment to show its activity and hyperglycemia to return to mild/moderate level before', 'dosing. The subject would then be dosed at the next scheduled visit (i.e., 6 weeks after the', 'previous infusion). Fasting blood glucose levels must return to mild/moderate severity before the', 'next scheduled infusion. The above process of withholding a scheduled infusion will be', 'permitted only twice during the study.', 'Any changes to the scheduled dosing interval (q3W) or adjustments in the infusion rate should', 'be reported to the Sponsor/CRO.', '9.4.7 Method of Assigning Subjects to Treatment Groups', 'All subjects will receive teprotumumab in this open-label extension study.', '9.4.8 Masking and Unmasking', 'This is an open-label extension study.', 'In order to maintain the study mask in HZNP-TEP-301 all subjects in this open-label extension', 'study will undergo the same dosing regimen of teprotumumab (10 mg/kg on Day 1 followed by', '20 mg/kg q3W for the remaining 7 infusions), regardless if they received teprotumumab or', 'placebo in HZNP-TEP-301.', '9.4.9 Concomitant Therapy and Restricted Medications', 'Local supportive measures for TED, simple analgesics (e.g., acetaminophen, non-steroidal anti-', 'inflammatory therapies), and medications/supplements for conditions other than TED are', 'permitted during the study. Topical corticosteroids for conditions other than TED are allowed;', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 79 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'however, oral corticosteroid use during the study is restricted to subjects who experience', 'infusion-associated AEs.', 'Symptomatic treatment (e.g., antipyretics, antihistamines, beta-agonists, oxygen, IV fluid) may', 'be administered to subjects who experience immediate infusion-associated AEs. Following the', 'appearance of either immediate or delayed infusion-associated events, subsequent dosing of', 'study drug may be pre-treated with diphenhydramine (1 to 1.25 mg/kg IV; maximum of 50 mg),', 'ranitidine (50 mg IV), famotidine (0.5 mg/kg IV), dexamethasone (0.4 mg/kg IV; maximum of', '20 mg), and/or acetaminophen (500 mg).', '9.4.9.1 Restricted Therapy and Medications', 'Subjects with a previous orbital irradiation or surgery for TED or who have a planned orbital', 'irradiation or surgery for TED over the course of this study are not eligible for study enrollment.', 'In addition, oral corticosteroids, selenium, biotin, immunosuppressive agents, investigational', 'agents, and illicit drug/alcohol use are restricted as shown in Table 9.1.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 80 of 118']\n\n###\n\n", "completion": "END"}